Eric Keith Rowinsky
457 works · 41,191 citations · h-index 90
Top works
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
- Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
- Taxol: A Novel Investigational Antimicrotubule Agent
- Paclitaxel (Taxol)
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
- Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
- Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.
- Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
- The Current Status of Camptothecin Analogues as Antitumor Agents
- Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
- Phase I trial of taxol in patients with advanced cancer.
- The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
- Cardiac disturbances during the administration of taxol.
- Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.
- Clinical toxicities encountered with paclitaxel (Taxol).
- Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)